Pluri Expands Manufacturing Agreement With Remedy Cell, Advances Clinical-Grade Production

Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. ("Remedy Cell"), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.

Under the ongoing collaboration Remedy Cell's personnel, along with Pluri's Contract Development and Manufacturing Organization ("CDMO") division (PluriCDMO™), have successfully completed the full implementation of Remedy Cell's proprietary manufacturing process into Pluri's state-of-the-art Good Manufacturing Practice ("GMP") facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell's lead candidate. These batches are intended for use in Remedy Cell's initial Phase 1b clinical trial, representing a major step in its clinical development. This achievement reflects the strong synergy between Remedy Cell's innovative therapeutic platform and Pluri's advanced manufacturing facilities.

The completion of these activities demonstrates PluriCDMO™'s potential to serve complex cell-derived and cell-free processes with consistent, scalable, and regulatory-compliant manufacturing solutions. For Remedy Cell, this milestone marks tangible progress on its path toward clinical development and the realization of its mission to bring secretome-based therapies to patients with fibrotic diseases.

Building on this success, Pluri and Remedy Cell are now broadening the scope of their collaboration. PluriCDMO™ will continue to provide additional manufacturing and process-development support as Remedy Cell advances its clinical and pre-commercial programs. The expanded activity underscores the productive partnership between the teams and their shared commitment to advancing next-generation, cell-free biologics that address significant unmet medical needs.